CAMBRIA-2 is a new clinical trial that aims to prevent breast cancer from coming back. CAMBRIA-2 is investigating if we can prevent breast cancer recurrence for patients with early-stage oestrogen receptor-positive, HER2-negative breast cancer, who have a medium to high risk of the cancer returning. CAMBRIA-2 will test if giving a new hormone therapy treatment, known as a ‘Selective Estrogen Receptor Degrader’ (SERD), is better at stopping cancer from returning, compared to the usual hormone the

A new clinical trial is exploring better treatment options for young women with the most common form of breast cancer. The OLIO trial builds on earlier research that identified a unique tumour feature in premenopausal women with hormone receptor (HR) positive, HER2 negative breast cancer - a subtype that can be more aggressive in younger women. OLIO is investigating whether targeted therapy with olaparib, or olaparib combined with durvalumab, added to standard chemotherapy before surgery, can mo